Vittail LTD - IO Private
#

Ygal Haupt

Professor

DD Checklist

How much total funding has your startup received

AUD 300,000 + matched AUD 280,000 (CSIRO), + in kind AUD 250,000 (Vittail)

What percentage do the founders still own?

70%

Did you develop your own technology inhouse?

Yes

What is your Annual Revenue Run Rate?

N/A

What is your most important metric (name and amount)?

● Prostate cancer is the most diagnosed malignancy and the second leading cause of cancer death in men in Western countries. In the US alone, >200,000 newly diagnosed cases of prostate cancer annually, and >3 million are estimated to be living with prostate cancer. The global market for prostate cancer therapeutics is conservatively valued at US$18billion annually. ● Human Papilloma Virus (HPV) related cancers constitute 5% of all human cancer, with a conservative estimate of >US$3B annually for HPV-cancer therapeutics.

Do you own Trademarks or Patents? (please list)

Yes

Vittail owns the rights to all of the project know-how that has been developed to date. Vittail has not filed IP to-date in order to ensure the longest possible window to the expiry of the priority date for the IP, and to minimize premature disclosure. Vittail and its patent attorneys (FB Rice) reviewed the patent databases and found no potential issue with respect to freedom to operate (FTO).

Vittail LTD

1.5M AUD

Amount Being Raised

Vittail is a Victorian-based company that has been established to develop novel solutions for difficult-to-treat common cancers. Vittail’s approach to developing drugs for cancer treatment is to protect the body’s innate defence processes that naturally prevent or resist cancer, but are corrupted during cancer development. Vittail has developed a platform of proprietary assays that gives it a unique position to develop new therapeutics for cancer and has secured all relevant assets pertaining to development, including IP. Vittail will also develop related biomarkers kits for commercialization. Vittail’s strategy is to seek an early commercialisation of its assets to Pharma. Vittail has links with Pharmas both directly and through its partners. Vittail is raising funds to reach an inflection point by demonstrating proof of concept for Vittail’s therapeutic solution.

Share this: